This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Varghese, S. Articles by Martuza, R. L. Search for Related Content PubMed PubMed Citation Articles by Varghese, S. Articles by Martuza, R. L.

Systemic Oncolytic Herpes Virus Therapy of Poorly Immunogenic Prostate Cancer Metastatic to Lung

Authors' Affiliations: ¹ Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Charlestown, Massachusetts; ² Department of Surgery (Neurosurgery), Harvard Medical School; and ³ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts

Requests for reprints: Samuel D. Rabkin, Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Simches Research Center, 185 Cambridge Street, CPZN-3800, Boston, MA, 02114. Phone: 617-726-6817; Fax: 617-643-3422; E-mail: rabkin{at}helix.mgh.harvard.edu.

Purpose: Our goal was to evaluate whether systemic administration of NV1042, an interleukin-12 (IL-12)–expressing oncolytic herpes simplex virus, and its noncytokine parental vector NV1023 are effective against preexisting metastatic prostate cancer in an immunocompetent mice model.

Experimental Design: Metastatic TRAMP-C2 lung tumors established in C57Bl/6 or nude mice were treated on day 21 with four i.v. administrations of NV1042 or NV1023 and sacrificed on day 42 to assess virus efficacy and the potential mechanism of efficacy.

Results: NV1042 or NV1023 treatment was similarly effective in eliminating extrapleural and hemorrhagic tumors present in mock-treated mice. However, NV1042 was further effective compared with NV1023 in controlling the growth of lung tumors (as determined by mean surface tumor nodule number, lung weights, and surface tumor burden) and in extending survival. NV1042-treated mice exhibited a transient increase of serum IL-12 1 day posttreatment, whereas IL-12 levels in tumor bearing lungs persisted a further 2 days at least. Only splenocytes from NV1042-treated mice secreted IFN- in response to TRAMP-C2 stimulation and displayed natural killer activity. The IL-12-mediated enhancement observed with NV1042 in the syngeneic model was abrogated in athymic mice treated in a similar manner, thus indicating a role for T cells in the augmented efficacy of NV1042 virus.

Conclusions: Systemic administration of the IL-12-expressing NV1042 virus is more effective than its noncytokine parent, NV1023, against preestablished metastatic lung tumors. Given the clinical safety profile of NV1020, the parental vector of NV1023, and NV1042's enhanced efficacy and ability to activate the host immune system, NV1042 merits clinical consideration for treating metastatic prostate cancers.

This article has been cited by other articles:

				S. Varghese, S. D. Rabkin, G. P. Nielsen, U. MacGarvey, R. Liu, and R. L. Martuza Systemic Therapy of Spontaneous Prostate Cancer in Transgenic Mice with Oncolytic Herpes Simplex Viruses Cancer Res., October 1, 2007; 67(19): 9371 - 9379. [Abstract] [Full Text] [PDF]